Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497808 | 0.76 | CA12 (0.36) | NAMPTCA12CA9CA1CA2 | |
| SCHEMBL23269745 | 0.76 | NAMPT (0.38) | NAMPTCA12CA9CA1KDM4C | |
| SCHEMBL965808 | 0.74 | NAMPT (0.35) | NAMPTCA12CA9CA1CA2 | |
| SCHEMBL965807 | 0.74 | NAMPT (0.37) | NAMPTCA12CA9CA1 | |
| SCHEMBL6207217 | 0.72 | MEN1 (0.38) | NAMPTCA12CA9CA1CA2 | |
| SCHEMBL6207215 | 0.72 | CA12 (0.36) | NAMPTCA12CA9CA1CA2 | |
| SCHEMBL15474439 | 0.71 | KDM7A (0.34) | KDM7APHF8KDM2ACA12CA9 | |
| SCHEMBL18125071 | 0.71 | CA1 (0.37) | NAMPTCA12CA9CA1CA2 | |
| SCHEMBL10964801 | 0.71 | NAMPT (0.35) | NAMPTCA12CA9CA1KDM4C | |
| SCHEMBL25007406 | 0.70 | CA12 (0.34) | NAMPTCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |